Determination of Lipid Derangements in Human Immunodeficiency Virus Patients Undergoing Anti-Retroviral Therapy

Qamar Bashir; Zujaja Hina Haroon; Naveed Asif; Muhammad Qaiser Alam Khan; Eijaz Ghani; Syed Raza Jaffar

doi:10.51253/pafmj.v72i6.5810

Authors

Qamar Bashir Armed Forces Institute of Pathology/ National University of Medical Sciences (NUMS) Rawalpindi Pakistan
Zujaja Hina Haroon Armed Forces Institute of Pathology/ National University of Medical Sciences (NUMS) Rawalpindi Pakistan
Naveed Asif Combined Military Hospital, Quetta/National University of Medical Sciences (NUMS) Pakistan
Muhammad Qaiser Alam Khan Combined Military Hospital, Lahore/National University of Medical Sciences (NUMS) Pakistan
Eijaz Ghani Armed Forces Institute of Pathology/ National University of Medical Sciences (NUMS) Rawalpindi Pakistan
Syed Raza Jaffar Armed Forces Institute of Pathology/ National University of Medical Sciences (NUMS) Rawalpindi Pakistan

DOI:

https://doi.org/10.51253/pafmj.v72i6.5810

Keywords:

Acquired immunodeficiency syndrome (AIDS), Antiretroviral therapy (ART), Cholesterol, Human immunodeficiency virus (HIV), hyperlipidemia

Abstract

Objective: To determine lipid derangements in HIV-positive patients receiving anti-retroviral therapy (ART).

Study Design: Comparative cross-sectional study.

Place and Duration of study: Chemical Pathology Department, in cooperation with the Department of Virology at Armed Forces Institute of Pathology (AFIP), Rawalpindi Pakistan, from Mar 2019 to Mar 2020.

Methodology: In this study, two groups were made. In Group-1, lipid profile estimation was done in HIV patients without treatment. In contrast, lipid profile estimation was done after one year of treatment with anti-retroviral drugs in Group-2.

Results: One hundred and two HIV-positive subjects were included in our study. Of these patients, 88(86.27%) were males,and 14(13.73%) were females. Independent sample t-test revealed a statistically significant difference (p-value<0.05) in serum cholesterol, serum triglycerides, serum high-density lipoprotein (HDL-c), low-density lipoproteins (LDL) and very lowdensity lipoproteins (VLDL) between the two groups.

Conclusion: Hyperlipidemia in HIV patients getting anti-retroviral therapy (ART) exposes them to a high risk of coronary artery diseases and myocardial infarction. Hence lipid profile of patients getting ART must be regularly monitored, and hyperlipidemia, if present, should be managed.